Mebeverine Hydrochloride

Mebeverine, the active ingredient in Mebeverine Hydrochloride, is an antispasmodic (smooth muscle relaxant) presented as an oral dosage form for oral use. It is employed to alleviate abdominal cramping and pain associated with functional gastrointestinal disorders, particularly irritable bowel syndrome, in adult patients.

GNH USA supplies Mebeverine Hydrochloride as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverine Hydrochloride acts on the smooth muscle of the gastrointestinal tract to relieve spasm‑related conditions. - Irritable bowel syndrome (IBS): reduces the frequency and intensity of abdominal cramping, bloating and irregular bowel movements, improving overall comfort. - Functional bowel disorders: eases episodic intestinal spasms, helping to normalize transit and lessen discomfort during flare‑ups. - Colicky abdominal pain: diminishes painful spasmodic contractions of the gut, providing symptomatic relief during acute episodes.

Mebeverine Hydrochloride may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea or mild gastrointestinal upset - Dry mouth or throat irritation - Headache or light‑headedness - Dizziness or feeling of faintness

Serious or Rare Side Effects: - Allergic reactions such as rash, itching, or angioedema - Severe hypotension or fainting episodes - Cardiac arrhythmia or palpitations

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor for allergic reactions: discontinue if rash, swelling, or anaphylaxis occurs. - Use with caution in hepatic disease: evaluate liver enzymes periodically. - Avoid in patients with known hypersensitivity to mebeverine or related compounds. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mebeverine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase mebeverine plasma levels. - Concurrent antispasmodics: additive smooth‑muscle relaxation can lead to excessive hypotonia. - Drugs that prolong the QT interval: combined effect may raise arrhythmia risk.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance dry‑mouth side effect. - Antihypertensive medications: potential additive blood‑pressure lowering effect.